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ABSTRACT
Histone deacetylases are important targets for cancer therapeutics, but their 
regulation is poorly understood. Our data show coordinated transcription of HDAC1 and 
HDAC2 in lung cancer cell lines, but suggest HDAC2 protein expression is cell-context 
specific. Through an unbiased siRNA screen we found that BRCA1-associated protein 
1 (BAP1) regulates their expression, with HDAC2 reduced and HDAC1 increased in 
BAP1 depleted cells. BAP1 loss-of-function is increasingly reported in cancers including 
thoracic malignancies, with frequent mutation in malignant pleural mesothelioma. 
Endogenous HDAC2 directly correlates with BAP1 across a panel of lung cancer cell lines, 
and is downregulated in mesothelioma cell lines with genetic BAP1 inactivation. We find 
that BAP1 regulates HDAC2 by increasing transcript abundance, rather than opposing 
its ubiquitylation. Importantly, although total cellular HDAC activity is unaffected by 
transient depletion of HDAC2 or of BAP1 due to HDAC1 compensation, this isoenzyme 
imbalance sensitizes MSTO-211H cells to HDAC inhibitors. However, other established 
mesothelioma cell lines with low endogenous HDAC2 have adapted to become more 
resistant to HDAC inhibition. Our work establishes a mechanism by which BAP1 loss 
alters sensitivity of cancer cells to HDAC inhibitors. Assessment of BAP1 and HDAC 
expression may ultimately help identify patients likely to respond to HDAC inhibitors.
INTRODUCTION
The histone deacetylases (HDACs) are an ancient and 
highly conserved family of enzymes that catalyze removal of 
acetyl groups from lysine residues, antagonizing the effects 
of histone acetyl-transferases (HATs). The HDACs play key 
roles in epigenetic modulation of gene expression through 
their activity towards histones. However, a considerable 
proportion of the proteome is subject to reversible acetylation 
[1] and, as HDACs have activity towards a plethora of 
protein substrates, they are more accurately termed lysine 
deacetylases. They comprise two sub-families: eleven zinc-
dependent isoenzymes that are divided into class I (HDAC1, 
HDAC2, HDAC3, HDAC8), class IIa (HDAC4, HDAC5, 
HDAC7, HDAC9), class IIb (HDAC6, HDAC10) and class 
IV (HDAC11); plus seven NAD+-dependent sirtuins that 
form a functionally distinct class III (SIRT1-SIRT7) [2]. 
This multiplicity of HDACs reflects their diverse and tissue-
specific functions.
Class I HDACs are widely expressed and, within 
this class, HDAC1 and HDAC2 are most closely related. 
They have a near identical gene structure indicative of 
duplication from a common ancestor, and retain 86% amino 
acid sequence identity. HDAC1 and HDAC2 can homo- and 
hetero-dimerize, but are commonly found together in multi-
protein complexes on which their catalytic activity depends. 
HDAC1 and HDAC2 are predominantly nuclear, usually 
associated with chromatin and play key transcriptional roles, 
although they have also been implicated in splicing, mitosis, 
meiosis, DNA replication and DNA repair (reviewed in [3]).
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Controversy has raged over the redundancy or 
isoenzyme specificity of HDAC1 and HDAC2, with 
loss-of-function studies in mice delivering important yet 
sometimes conflicting data (reviewed in [3]). In germline 
knockouts, HDAC1 is embryonic lethal before E10.5, 
but HDAC2 null mice can survive until and beyond 
the perinatal period, perhaps suggesting independent 
functions. However, conditional isoenzyme knockouts 
have less severe phenotypes, and a compensatory 
mechanism is commonly seen, where deletion of HDAC1 
results in increased expression of HDAC2 protein, and 
vice versa. Combined conditional ablation of HDAC1 and 
HDAC2 has dramatic effects on proliferation, survival, 
and/or differentiation in most tissues and cell types. 
Ultimately, it has required models with deletion of 3 out of 
the 4 HDAC1 and HDAC2 alleles to allow elucidation of 
the overlapping but specific roles for HDAC1 and HDAC2 
during development.
Importantly, HDAC1 and HDAC2 are dysregulated 
in many human diseases including diabetes, asthma, 
neurological disorders and cancer. In breast or 
osteoscarcoma cells HDAC1, but not HDAC2, was 
required for proliferation and its depletion led to cell cycle 
arrest and apoptosis [4]. Intriguingly though, HDAC2 is 
specifically degraded in airway disease through stress-
responsive post-translational modifications (PTMs) 
triggered by cigarette smoke [5]. Both HDAC1 and 
HDAC2 are known to be phosphorylated, acetylated, 
ubiquitylated, SUMOylated, nitrosylated and alkylated 
(reviewed in [6]). Isoenzyme specific PTMs, particularly 
within the less well conserved C-terminal, may contribute 
to the context-specific redundancy or independent 
activities of HDAC1 and HDAC2 [6]. In the setting of 
reversible ubiquitylation, alternative ubiquitin E3 ligases 
have been identified for HDAC1 [7, 8] and HDAC2 
[9, 10], which either modulate their transcriptional 
activity or target them for proteasomal degradation, but 
no deubiquitylases (DUBs) have yet been identified that 
antagonize these functions.
Given their deregulation in cancer HDAC1 and 
HDAC2 are important therapeutic targets. First generation 
pan-HDAC inhibitors, such as vorinostat (SAHA), bind the 
active site Zn2+ ion critical for the function of class I, II and 
IV HDACS. Their anti-tumor activity is largely attributed 
to selective induction of cell cycle arrest and/or apoptosis in 
cancer cells [2]. Vorinostat was the first HDAC inhibitor to be 
licensed, for use in treatment of cutaneous T-cell lymphoma 
[11]. However vorinostat has shown limited efficacy in single 
agent trials for solid tumors [12]. Accumulating evidence 
that specific HDAC isoenzymes deacetylate distinct target 
proteins, and are differentially expressed in cancers, argues 
for the use of more specific HDAC inhibitors. Class I or class 
II selective inhibitors are available, and isotype-selective 
inhibitors are in development [13]. Identifying cellular targets 
that sensitize to HDAC inhibition may enable stratification of 
patients within trials.
We set out to investigate the co-expression of HDAC1 
and HDAC2 in lung cancer cell lines and to use an unbiased 
siRNA screen to identify DUBs that may regulate HDAC1 
and/or HDAC2 expression. We found that depletion of the 
tumor suppressor BAP1 reduced HDAC2 expression, acting 
at the level of transcription rather than ubiquitylation. This 
provides a clear mechanism by which BAP1 loss-of-function 
alters cancer cell sensitivity to specific HDAC inhibitors.
RESULTS
We initially investigated the interdependence 
of HDAC1 and HDAC2 expression, and evaluated 
the relative contribution of transcriptional or post-
transcriptional regulation towards their protein level 
expression. To this end, we simultaneously extracted total 
RNA and cellular protein from a panel of lung cancer 
cell lines for quantitative RT-PCR and immunoblotting 
(Figure 1A and 1B). The panel comprised cell lines 
derived from normal bronchial epithelium or fibroblasts, 
together with three small cell lung cancer (SCLC), one 
carcinoid and six non-small cell lung cancer (NSCLC) 
cell lines. We saw very tight correlation between the 
transcript levels of HDAC1 and HDAC2 across the eight 
non-neuroendocrine cell lines, with increased expression 
in NSCLC relative to normal lung (Figure 1A and 1C), 
suggesting that transcription of HDAC1 and HDAC2 
may be co-regulated. However, expression of HDAC1 
and HDAC2 were uncoupled in neuroendocrine cell lines, 
so that in each case one of the isoenzyme transcripts 
was markedly elevated relative to the other: HDAC2 in 
SCLC (NCI-H69, NCI-H345 and Lu-165) and HDAC1 
in the NCI-H727 carcinoid cell line (Figure 1A). In 
non-neuroendocrine cells, HDAC1 mRNA was a good 
predictor for the HDAC1 protein expression level, but this 
was not true for HDAC2 (Figure 1D). Thus, in a given 
cellular context, the level of HDAC2 may be largely 
dependent on post-transcriptional, translational or post-
translational regulatory mechanisms. As compensatory 
responses in protein expression are reported between the 
HDAC1 and HDAC2 isoenzymes in conditional knockout 
mice [3], and on siRNA depletion in osteosarcoma and 
breast cancer cell lines [4], we tested if this was also the 
case in A549 lung cancer cells. As predicted, we saw 
increased HDAC2 protein in HDAC1 depleted cells, 
and increased HDAC1 protein in HDAC2 depleted cells 
(Figure 1E).
HDAC1 and HDAC2 are both subject to ubiquitin-
mediated proteasomal degradation and several E3 ligases 
have been assigned [7–10]. However, ubiquitylation is a 
reversible process, and no DUBs have yet been described 
that may remove ubiquitin from HDAC1 or HDAC2. 
To identify DUBs that might be involved in specifically 
regulating the cellular abundance of either HDAC, we 
utilized a library of quality-controlled nucleoplasm lysates 
prepared from A549 NSCLC cells that had been depleted 
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of each of the 92 human DUBs using a custom siRNA 
library, as described previously [14, 15]. We screened 
by immunoblotting and ranked the ratio of expression 
for HDAC2 relative to HDAC1 (Figure 2A). This ratio 
will reflect both the decrease in one HDAC (for example 
where a DUB is depleted that might normally rescue it 
from proteasomal degradation) and the compensatory 
increase for the opposite HDAC isoenzyme (as shown in 
Figure 1E). Whilst USP33 or USPL1 depletion increased 
the HDAC2/HDAC1 ratio, we identified USP27X and the 
tumor suppressor BAP1 as DUBs whose depletion lead to 
the most significant decrease in the HDAC2/HDAC1 ratio. 
In the case of BAP1, this indeed reflected both a decrease in 
HDAC2 and an increase in HDAC1 expression (Figure 2A).
Figure 1: Interdependency of HDAC1 and HDAC2 expression in lung cancer cell lines. A. HDAC1 and HDAC2 transcript 
expression in lung cancer cells. RNA extracted from a panel of normal lung and lung cancer cell lines was assessed for HDAC transcript 
expression by qRT-PCR. Cq values for test genes were normalized to actin and expressed as 2–[∆∆Cq] relative to the BEAS2B cell line. 
B. Co-extracted proteins from the same cell lines were immunoblotted for HDAC1 and HDAC2. For correlation in subsequent panels, 
HDAC protein levels were quantified using Odyssey analysis software, normalized to tubulin and shown relative to the BEAS2B cell 
line. C. HDAC1 and HDAC2 transcripts (top), but not proteins (below), exhibit strong positive correlation in the NSCLC and normal 
lung cell lines. D. HDAC1 mRNA (top), but not HDAC2 mRNA (below), is a good predictor of protein expression. Scatter plots 
represent quantification of protein (x-axis) plotted against that of mRNA (y-axis). E. Depletion of HDAC1 or HDAC2 leads to isoenzyme 
compensation. A549 cells were transfected with 40 nM siRNAs as indicated. Whole cell protein extracts were prepared 72 hr later and 
equivalent amounts immunoblotted. Expression of each HDAC was normalized to actin and is indicated relative to the siC control.
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Figure 2: BAP1 regulates the balance of HDAC2 and HDAC1 expression. A. DUB siRNA library screen identifies BAP1 as a 
candidate regulator of class I HDACs. 72 hr after transfection with 40 nM siRNA pools against 92 human DUBs, their effect on HDAC1 
and HDAC2 expression was screened by immunoblotting of nuclear extracts from A549 lung cancer cells. The main histogram shows 
mean log(2) values for HDAC2 relative to HDAC1 from two immunoblots; DUBs of interest and two non-targeting controls (siCON1 
and siCON2) are indicated. Inset immunoblot panels show sections from the screen, highlighting DUB siRNAs that altered the HDAC 
expression ratio. The inset histogram shows an increase in HDAC1 and a decrease in HDAC2 expression for the siBAP1 samples from the 
replicate screens. B. BAP1 depletion decreases HDAC2 relative to HDAC1 in both cytosolic and nuclear protein extracts. A549 cells were 
transfected with 40 nM siRNAs for 72 hr. Quantification from immunoblotting shows the ratio of HDAC2 to HDAC1 expression from three 
independent experiments (error bars show SD, unpaired t-test, *P ≤ 0.05, **P ≤ 0.01). C. BAP1 depletion decreases HDAC2 and increases 
HDAC1 in other NSCLC cell lines. NCI-H460 or COR-L23 cells were transfected with 40 nM siRNAs for 72 hrs before immunoblotting 
of whole cell extracts. D–E. BAP1 siRNAs alter HDAC expression in MSTO-211H mesothelioma cells. Whole cell extracts were prepared  
72 hr after transfection with siRNAs. A representative immunoblot D. and quantification from three independent experiments E. showing the 
HDAC2/HDAC1 ratio (left), and individual proteins normalized to actin (right); error bars show SD, one-way ANOVA with Tukey’s post-
hoc test: ****P ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05. F. Quantification of residual BAP1 for the siRNA experiments in B and D.
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This initial screen used pools of four siRNA 
sequences to target each DUB. To assess whether 
off-target effects might be responsible for altering 
HDAC abundance, we next transfected A549 cells with 
independent siRNA sequences. Statistically, it is unlikely 
that more than one siRNA would have the same off-target 
effect, so our criteria were that at least two individual 
siRNAs targeting a DUB produced a similar change 
in the HDAC2/HDAC1 ratio. This was not the case for 
USP33 or USPL1, and was marginal for USP27X (data 
not shown). In contrast, a reduction in HDAC2/HDAC1 
was recapitulated by two siRNA sequences targeting 
BAP1 in A549 nucleoplasm extracts (Figure 2B). Both 
HDACs were also detected in cytosolic extracts, where 
their expression ratio was similarly affected by BAP1 
siRNAs (Figure 2B), confirming that BAP1 depletion 
effects a change in abundance rather than sub-cellular 
relocalisation. BAP1 knockdown elicited this same switch 
in HDAC2/HDAC1 expression in two other NSCLC 
cell lines (Figure 2C), which endogenously express 
these HDACs at different levels (Figure 1B). As loss 
of BAP1 function is implicated in a high proportion of 
mesothelioma [16–19], we next asked whether we could 
recapitulate this effect in MSTO-211H cells, which were 
derived from a grade 4 biphasic mesothelioma and retain 
wild-type BAP1 expression [19]. Depletion of BAP1 
consistently reduced HDAC2 and increased HDAC1 
expression in whole cell protein extracts from these cells 
(Figure 2D & 2E). As before, siBAP1–3 more profoundly 
affected the HDAC2/HDAC1 expression ratio than 
siBAP1–5. Effects of BAP1 depletion were more marked 
in the MSTO-211H cells than in A549 cells, due to the 
relative knockdown efficiencies (Figure 2F).
In light of the effect of transient BAP1 depletion on 
HDAC expression, we hypothesized that variation in the 
endogenous expression of BAP1 in cancer cells may also 
influence HDAC levels. BAP1 is expressed to varying 
degrees across the panel of SCLC, NSCLC and normal 
lung cell lines, and is relatively under-expressed in the 
A549 cell line (Figure 3A) in which we had performed our 
initial screen (Figure 2A). In contrast, BAP1 is elevated 
in the SCLC cell lines, which express HDAC2 at high 
Figure 3: Endogenous BAP1 and HDAC2 expression are positively correlated. A–B. Protein extracts from the panel of SCLC, 
NSCLC and normal lung derived cell lines shown in Figure 1B were analyzed for BAP1 expression. A representative immunoblot A. and 
quantification of relative protein expression B., showing that HDAC2 protein levels correlate with those of BAP1 in non-neuroendocrine 
cells (linear regression R2 = 0.68). C–D. Immunoblotting in normal mesothelial cells and mesothelioma cell lines with differing genetic 
BAP1 status. A representative immunoblot C. and quantification of relative protein expression from three independent experiments D. show 
HDAC2 protein levels correlate with those of BAP1. NCI-H2052 cells are an outlier and have genetic loss of HDAC2 copy number (linear 
regression for other cell lines, R2 = 0.98).
Oncotargetwww.impactjournals.com/oncotarget 13762
levels. Overall, we found a significant positive correlation 
between BAP1 and HDAC2 levels, as illustrated for the 
seven NSCLC and two normal lung cell lines in Figure 
3B. In contrast there was no correlation between HDAC1 
and BAP1 expression (linear regression R2 = 0.11).
As BAP1 depletion had a profound effect on the 
HDAC2/HDAC1 expression ratio in MSTO-211H cells 
(Figure 2D & E), we next examined the relationship 
between endogenous HDAC2 and BAP1 mutation status in 
a panel of established mesothelioma cell lines (Figure 3C). 
The MeT-5A cell line is derived from normal lung 
mesothelium, whilst the mesothelioma cell lines have 
differing BAP1 genetic status [19]: NCI-H2052 and MSTO-
211H cells retain genetically wild-type BAP1, NCI-H28 
and NCI-H226 cells are BAP1 null, and NCI-H2452 
cells have an inactivating mutation in the BAP1 catalytic 
domain. Immunoblotting confirmed that BAP1 protein 
was expressed in the three wild-type lines, and was absent 
in the BAP1 null mesothelioma cell lines (Figure 3C). 
Very low levels of BAP1 were detected in NCI-H2452 
cells, suggesting that BAP1 auto-deubiquitylation is not 
only required for nuclear localization [20] but perhaps 
also stability in these cells. Both HDAC1 and HDAC2 
were expressed in the normal mesothelial MeT-5A 
cells, and HDAC1 was expressed at varying levels in 
the mesothelioma cell lines (Figure 3C). As predicted, 
HDAC2 expression was low in BAP1 null mesothelioma 
cell lines and overall showed a tight correlation with BAP1 
expression status (Figure 3C & D). A notable exception 
was the NCI-H2052 cell line, which has loss of HDAC2 
copy number (COSMIC, [21]) that likely accounts for low 
expression of HDAC2 even in the presence of BAP1.
This correlative expression further supported our 
functional data showing that BAP1 regulates HDAC2, 
so we investigated whether BAP1 might directly 
deubiquitylate and thus stabilize HDAC2. We first assessed 
whether inhibition of the proteasome led to accumulation of 
HDACs (Figure 4A). In BAP1 wild-type MSTO-211H cells 
we saw a marginal increase in HDAC2 levels in response 
to epoxomicin. Although we might expect a more profound 
response in BAP1-null cells, in fact we saw no increase in 
HDAC protein levels on epoxomicin treatment of NCI-H28, 
suggesting that turnover of HDAC2 is not a major limitation 
for its expression in this cell line. To determine whether 
HDAC2 turnover is BAP1-dependent in MSTO-211H cells, 
we compared rescue by proteasome inhibition in siRNA-
transfected cells (Figure 4B). Expression of the labile 
protein P53 was clearly rescued by proteasome inhibition, 
and this was comparable between the knockdown 
conditions. As before, HDAC2 rescue by proteasome 
inhibition was modest, and was similar in BAP1-depleted or 
control cells. In addition, we found that BAP1 depletion did 
not reduce the stability of residual HDAC2 under conditions 
where translation was blocked (Figure 4C). Together these 
data suggest that BAP1 does not salvage HDAC2 from 
ubiquitin-mediated proteasomal degradation.
BAP1 is known to regulate H2A monoubiquitylation, 
as well as the polyubiquitylation of a number of 
transcription factors, so we wondered whether BAP1 
might instead control transcription of HDAC2. To test this, 
we performed qRT-PCR in siRNA-transfected MSTO-
211H cells and observed a marked decrease in HDAC2 
transcript levels in cells depleted of BAP1 (Figure 4D). 
Indeed, we observed a strong correlation between HDAC2 
protein (Figure 2E) and HDAC2 mRNA expression in 
these experiments (Figure 4E). In contrast, HDAC1 levels 
were not significantly affected by BAP1 depletion, and did 
not correlate with HDAC1 protein levels. We conclude 
that BAP1 primarily exerts its effects through regulating 
HDAC2 transcript abundance, which is coupled with 
compensation in HDAC2/HDAC1 protein expression.
To establish whether the BAP1-dependent changes in 
HDAC1 and HDAC2 expression impact on overall cellular 
HDAC activity, we assayed the enzymatic activity of cell 
extracts towards an artificial HDAC-GloI/II substrate. 
In A549 cells, chronic treatment with the pan-HDAC 
inhibitor TSA abolished 75% of cellular HDAC activity 
as determined by this assay (Figure 5A). However, siRNA 
depletion of HDAC1, HDAC2 or BAP1 did not lead to 
significantly different cellular HDAC activity, suggesting 
that in each case the compensatory isoenzyme response 
maintains overall activity levels (Figure 5B and 5C). In 
MSTO-211H cells, acute treatment with vorinostat again 
reduced HDAC activity (Figure 5D), but we confirmed that 
depletion of either HDAC, or of BAP1, had no significant 
impact (Figure 5E and 5F).
Although total HDAC activity was unchanged, we 
were interested to determine whether the BAP1-dependent 
switch in the HDAC2/HDAC1 isoenzymes affected cell 
viability when combined with HDAC inhibitors. We 
initially established the lethal concentration 30% for 
drugs that exhibit pan- or class-selective HDAC inhibition 
in MSTO-211H cells (Figure 6A). We next assessed the 
effects of BAP1 or HDAC siRNA on cell viability. While 
HDAC1 depletion had little effect, depletion of HDAC2 
significantly reduced cell viability, suggesting that MSTO-
211H cells are dependent on HDAC2 for survival (Figure 
6B, DMSO). Importantly, BAP1 depletion also reduced 
viability. This effect was more pronounced for siBAP1–3 
than for siBAP1–5, mirroring their respective effects on 
HDAC2 expression (Figure 2).
We then explored whether MSTO-211H cells 
depleted of these proteins would be more sensitive to 
HDAC inhibitors applied at their LC30 (Figure 6C). 
None of the siRNA transfected cells were significantly 
sensitized to the class IIa selective inhibitor MC1568. 
Neither did addition of pan-HDAC (vorinostat) or of 
class I selective (mocetinostat) inhibitors significantly 
influence the survival of HDAC1 depleted cells. In 
contrast, HDAC2 depleted cells were sensitized to both 
HDAC inhibitors, with significantly decreased viability 
compared to DMSO alone. Importantly, BAP1 knockdown 
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Figure 4: BAP1 regulates HDAC2 at the transcript level. A. HDAC response to proteasome inhibition. Cells were treated with 50 nM 
epoxomicin (Epo) for 6 hr prior to whole cell lysis and immunoblotting. A representative immunoblot (top) and quantification of proteins from 
three independent experiments (below), error bars show SD. B. The effect of BAP1 depletion on HDAC2 levels is not rescued by proteasome 
inhibition. MSTO-211H cells were transfected with siRNAs for 72 hr and treated with 50 nM epoxomicin for the final 6 hr prior to whole cell 
lysis and immunoblotting. A representative immunoblot and quantification of proteins showing epoxomicin treated relative to untreated for 
each knockdown condition (three independent experiments, error bars show SD, no significant difference was determined between samples 
using one-way ANOVA with Dunnett’s post-hoc test). C. BAP1 depletion does not significantly alter HDAC2 protein stability. MSTO-211H 
cells were transfected with siRNAs and treated with 10 μg/ml cycloheximide for the indicated times prior to whole cell protein extraction 
and immunoblotting. A representative immunoblot and quantification of HDACs (four independent experiments, error bars show SD, no 
significant difference was determined between samples by paired t-test). D. BAP1 depletion decreases HDAC2 mRNA. MSTO-211H cells 
were transfected with siRNAs as indicated and RNA extracted 72 hr later for qRT-PCR. Cq values for test genes were normalized to actin and 
expressed as 2-[∆∆Cq] relative to the siC control (three independent experiments, error bars SD, one-way ANOVA with Dunnett’s post-hoc test: 
****P ≤ 0.0001, ***P ≤ 0.001). E. On depletion of BAP1, HDAC2 transcript is a good predictor of HDAC2 protein expression level.
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also increased sensitivity to HDAC inhibition in a similar 
fashion, decreasing cell survival with both vorinostat and 
mocetinostat.
In dose response curves, the LC50 of vorinostat 
halves from 2.6 μM in siC-treated cells to 1.3 μM with 
HDAC2 siRNA and 1.2 μM in BAP1 depleted cells. 
Crucially, concomitant BAP1 and HDAC2 depletion did not 
additively reduce cell viability in the presence of vorinostat 
(Figure 6D). This is consistent with loss of BAP1 mediating 
increased drug sensitivity through its ability to lower 
HDAC2 levels. Lastly, we assessed the relative HDAC 
inhibitor sensitivity of three established mesothelioma cells 
with constitutively low HDAC2 expression together with 
the MSTO-211H cells that retain high HDAC2 expression 
(Figure 3C). Intriguingly, in contrast to our data for transient 
HDAC2 knockdown, the constitutively HDAC2-deficient 
mesothelioma cell lines were more resistant to mocetinostat 
(Figure 6E). We found that the LC50 of the HDAC2-
deficient lines NCI-H2052, NCI-H28 and NCI-H226 was 
4.0, 4.5 and 4.9 μM, respectively, compared to 2.4 μM for 
MSTO-211H cells. Furthermore, in the HDAC2-deficient 
lines, around a third of cells remained viable at much 
higher doses, suggesting they have adapted to become less 
dependent on HDAC2 for viability.
In conclusion, loss of BAP1 in cell line models of 
thoracic malignancies alters expression of HDAC2. This 
in turn modulates the sensitivity of these cells to clinically 
relevant HDAC inhibitors.
DISCUSSION
We report here an unbiased DUB siRNA screen 
that has identified BAP1 as a regulator of HDAC2 
expression in lung cancer and mesothelioma cells. BAP1 
Figure 5: Neither HDAC nor BAP1 depletion alters total cellular HDAC activity. HDAC activity was assessed in A549 
cells A–C. and MSTO-211H cells D–F. As positive controls, cells were A. chronically treated with 250 nM of the pan-HDAC inhibitor 
TSA for 16 hr (mean of two independent experiments), or D. acutely treated with 5 μM vorinostat for 2 hr (mean of three independent 
experiments, error bar SD). BAP1 depletion does not affect activity towards the HDAC-GloI/II substrate. Cells were reverse transfected 
with 20 nM siRNA as indicated for 48 hr. Immunoblotting shows efficient depletion by reverse transfection of siRNA in the 96-well assay 
format, B. E., the percentage efficiency for depletion of the target protein (KD%) and the ratio of HDAC2/HDAC1 expression (H2/H1) is 
indicated. For the HDAC-Glo assay run in parallel, C. F., data show the mean of three (C.) or four (F.) independent experiments (error bars 
SD, no significant difference was determined between samples using one-way ANOVA with Dunnett’s post-hoc test).
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Figure 6: BAP1 status alters sensitivity of mesothelioma cells to HDAC inhibitors. A. Dose response curves for HDAC 
inhibitors in MSTO-211H cells. Vorinostat (broad spectrum), mocetinostat (class I) and MC1568 (Class IIa) were added to cells at the 
indicated concentrations for 48 hr prior to CellTitre-Glo assay (error bars show SD of 4 technical replicates). MC1568 remains in aqueous 
solution at concentrations below 50 μM. B–D. HDAC2 or BAP1 depletion sensitizes cells to HDAC inhibitors. MSTO-211H cells were 
reverse transfected with 20 nM siRNA for 72 hr, and treated with vehicle (0.1% DMSO) B. or with HDAC inhibitors C. D. for the final 48 
hr, before viable cell estimation by CellTitre-Glo assay (error bars show SD for three independent experiments). B. Treatment with vehicle: 
relative viability is plotted, compared to cells transfected with the siC control and treated with vehicle (one-way ANOVA with Tukey’s  
post-hoc test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001). C. Treatment with the indicated HDAC inhibitors at their LC30: 20 μM MC1568, 
2.5 μM vorinostat and 1.25 μM mocetinostat. The relative viability is plotted as a histogram for each drug treatment, this is based on 
comparison to cells transfected with siC and treated with that drug. For each bar on the histograms, percentage viability is also indicated, 
which compares the drug treated cells to the DMSO treated cells (shown in B) for the same knockdown condition; statistical significance 
for this comparison is shown (one-sample t-test, *P ≤ 0.05, **P ≤ 0.01). D. Dose response curves for vorinostat in HDAC2 and/or BAP1 
depleted MSTO-211H cells; all data are normalized to siC transfected cells in 0.1% DMSO. E. Dose response curves for mocetinostat in a 
panel of mesothelioma cell lines with high (MSTO-211H) or low (other cell lines) constitutive HDAC2 expression. Data are normalized to 
0.1 μM treatment for each cell line (error bars show SD for three independent experiments).
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was first identified as tumor suppressor, when mutations 
were reported in lung cancer cell lines [22]. In fact, 
somatic BAP1 mutation occurs in only around 1% of 
lung adenocarcinoma [23, 24], but is far more prevalent 
in uveal melanoma [25, 26], mesothelioma [18, 19] and 
renal clear cell carcinoma [27]. Germline BAP1 mutation 
underpins a cancer predisposition syndrome [18, 25, 
26, 28–30] and BAP1 protein expression is reportedly 
lost in around 50% of NSCLC, colon carcinoma, uveal 
melanoma and kidney cancers [31–37]. Mechanistically, 
BAP1 removes monoubiquitin from histone H2A 
[38], or stabilizes proteins like BRCA1 and HCFC1 by 
removing polyubiquitin chains [22, 39, 40], whilst many 
transcription factors and chromatin modifiers have been 
identified as BAP1 interacting proteins [41, 42].
Here we show for the first time that BAP1 
modulates expression of another chromatin-associated 
protein, HDAC2. However, this is mediated not through 
direct deubiquitylation of HDAC2, but through regulating 
HDAC2 transcript abundance. Loss of BAP1 increases 
H2A monoubiquitylation, which is transcriptionally 
repressive, suggesting one route by which this may 
be mediated. However, indirect effects of BAP1 via 
transcription factors that control HDAC2 transcription, 
or through alteration of HDAC2 transcript stability, 
might also play roles. We find that BAP1 loss promotes 
a switch from HDAC2 to HDAC1. This arises due to a 
well-established reciprocal compensatory mechanism, 
so that when HDAC2 levels drop, HDAC1 levels 
rise. In cell lines and in transgenic mice, this crosstalk 
between HDAC1 and HDAC2 is not mediated by altered 
transcription, but through changes in either protein 
synthesis or turnover [43, 44].
It is interesting that our current screening strategy 
did not uncover any DUBs that reverse HDAC2 
polyubiquitylation and so stabilize the HDAC2 protein. 
In fact, our data also suggest that HDAC2 turnover by 
proteasomal degradation may not be a major determinant 
of its abundance under normal growth conditions in 
these cell lines. Strategies to stimulate HDAC2 turnover, 
such as the response to cigarette smoke [5], may aid 
future screens for DUBs that directly antagonize 
ubiquitylation of HDAC2.
When we compared HDAC expression in a panel 
of cell lines, we found that HDAC2 transcript abundance 
was not a good predictor of HDAC2 protein level 
(Figure 1D). This is not unusual, in fact global studies 
report that the major determinant of protein abundance 
is neither transcription nor protein degradation, but is 
instead translation [45]. Intriguingly though, when we 
deplete BAP1 leading to a reduction in HDAC2 mRNA, 
this transcript now becomes a good predictor of HDAC2 
protein expression (Figure 4E). Taken together, these data 
suggest that although HDAC1 and HDAC2 are normally 
co-transcribed, the HDAC2 transcript is in excess of the 
cellular requirements for HDAC2 protein. However, in 
the absence of BAP1 their transcription is disengaged and 
availability of HDAC2 mRNA may now limit HDAC2 
protein expression.
The clinical relevance of BAP1 loss-of-function 
in mesothelioma remains under debate, with conflicting 
reports that it may be preferentially associated with 
epithelioid morphology, later age of presentation, or 
overall survival [16, 19, 36, 46] and there are as yet no 
studies that provide a rationale for specific targeted 
therapies. Up to 80% of mesothelioma are directly 
attributable to asbestos exposure [47] and it was recently 
shown that mice with heterozygous germline BAP1 
knockout were predisposed to develop mesothelioma 
upon asbestos exposure [48]. Interestingly, somatic BAP1 
mutation is reported to be more common in current or 
ex-smokers who develop mesothelioma [46] and could 
conceivably compound HDAC2 instability in response to 
cigarette smoke [5].
BAP1 loss might also be associated with cancer 
progression and metastasis. Clinically BAP1 mutation 
was initially linked to more aggressive, metastasizing 
uveal melanoma [26], whilst subsequent cell models 
suggested that BAP1 loss induces a stem cell-like 
phenotype [49]. In mesothelioma, BAP1 loss is 
more common in a clinical sub-group that exhibit 
less evidence of EMT [50], but on asbestos exposure 
BAP1+/– mice develop more aggressive tumors, that 
invade other organs, than their wild-type littermates 
[48]. In the absence of a carcinogenic insult however, 
BAP1 loss may not promote cell growth. Indeed uveal 
melanoma cells stably expressing BAP1 shRNA show no 
difference in their in vitro or in vivo growth kinetics [49] 
and BAP1+/– mice do not spontaneously develop tumors 
[48]. In several studies, BAP1 loss is in fact reported to 
slow cell growth through a delayed but more permissive 
G1/S cell cycle checkpoint [19, 40]. Indeed, on transient 
BAP1 depletion in MSTO-211H cells, we observed 
an approximate 50% reduction in viable cell number, 
comparable with previous data for this cell line [19].
These data suggest cytotoxic drugs targeting 
rapidly dividing cells are not apposite for BAP-deficient 
mesothelioma. Indeed, mesothelioma shows low chemo- 
and radio-sensitivity and targeted therapies are urgently 
required [51]. Synthetic lethal approaches offer new 
opportunities to exploit essential survival pathways in 
cancer cells with BAP1 loss-of-function. Several cancer 
drugs have been identified that exhibit synthetic lethality 
with specific tumor suppressors, most notably BRCA1 
mutation/PARP inhibitors [52]. As BAP1 interacts with 
BRCA1, PARP inhibitors might also exhibit synthetic 
lethality with BAP1 mutation. However, whilst this was 
seen in BAP1 knockout chicken lymphoma cells [53], no 
synthetic effects were found in human mesothelioma cells 
[19] emphasizing the importance of cellular context. Our 
initial data suggest a potential relationship between BAP1 
and HDAC inhibitors that could be exploited instead.
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Despite early promise, histone deacetylase inhibitors 
have failed to show significant clinical activity in solid 
tumors. In mesothelioma for example, while an early 
phase trial found some evidence for activity of vorinostat, 
a subsequent large phase III study did not show any 
benefit for vorinostat in second line treatment [54, 55]. 
The failure of this trial understandably led to a dampening 
of enthusiasm for HDAC inhibitors in mesothelioma. It is 
however feasible that the lack of benefit in the overall trial 
could mask a subgroup of patients who derived benefit 
from treatment. The need to stratify NSCLC patients 
based on EGFR mutation for EGFR inhibitor clinical trials 
[56–58] highlights the importance of identifying 
biomarkers that can predict for response.
We found that despite the effect on HDAC2 
expression, loss of BAP1 does not impact on total cellular 
HDAC activity, suggesting the compensatory increase 
in HDAC1 maintains cellular HDAC activity. This is 
consistent with other reports of the HDAC relationship, 
for example in mice with targeted inactivation of either 
HDAC1 or HDAC2 in the epidermis, there is reciprocal 
upregulation of the opposite isoenzyme with no reduction 
in total HDAC activity [43]. Specific roles for the class I 
HDAC isoenzymes are however increasingly recognized, 
and this BAP1-dependent switch in the prevalence of 
HDAC1 and HDAC2 may have functional implications. 
Indeed we find that HDAC2 appears more important than 
HDAC1 in maintaining viability of the BAP1 positive 
mesothelioma cell line MSTO-211H. Of particular 
importance in a clinical setting, this could impact on the 
sensitivity of cancer cells to HDAC inhibitors. Despite 
the maintenance of total HDAC activity, we found 
increased sensitivity to HDAC inhibitors on depletion of 
HDAC2 or BAP1, but not of HDAC1 (Figure 6). This 
lends support to HDAC isoenzyme-specific roles, and 
suggests HDAC2 specific inhibitors might enable more 
precise targeted therapy.
The relationship between BAP1 expression and 
HDAC inhibitor sensitivity has not previously been 
explored in mesothelioma. In uveal melanoma cell lines, 
HDAC inhibitors partially rescue the loss of melanocytic 
differentiation associated with BAP1 depletion [49,  59]. 
Furthermore, stable BAP1 depletion in a uveal melanoma 
cell line leads to sensitization to the HDAC inhibitor 
valproic acid and decreased viability. Although changes 
in H2A ubiquitylation status were observed in this 
experiment [59], the mechanism for HDAC inhibitor 
sensitization remains unclear. Our data, which show 
HDAC2 expression to be contingent on BAP1, provide 
the first mechanism to underpin differential sensitivity of 
BAP1-deficient cells to HDAC inhibitors.
Significantly however, our data show that transient 
loss of BAP1 expression is not equivalent to its genetic 
inactivation in cell lines that have been in long term culture, 
raising a number of points. Firstly, siRNA screening has 
allowed us to identify a new target of the deubiquitylase 
BAP1; however inferring clinical biomarkers from 
transient depletion of BAP1 might give deceptive results. 
Indeed, our data suggest that cells adapt to genetic BAP1 
loss, such that sensitivity to HDAC inhibitors is reduced. 
While our findings will need to be confirmed in other 
models, this is potentially of clinical significance, as HDAC 
inhibitors are currently being investigated in clinical 
trials for uveal melanoma in which BAP1 mutations are 
common. On the other hand, our data suggest that cancer 
cells develop compensatory mechanisms to survive without 
BAP1; identifying these mechanisms may provide new 
opportunities for synthetic lethal strategies. Well-defined 
models of genetic BAP1 loss are now needed to allow 
screening for biomarkers and new targets. These, alongside 
clinical studies to assess the prevalence of BAP1-dependent 
HDAC2 loss, will help establish how BAP1 status affects 
pan or class-selective HDAC inhibitor sensitivity.
MATERIALS AND METHODS
Cell culture
A549 cells (obtained from ECACC) were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 
1% non-essential amino acids, at 37°C and 5% CO2. 
The mesothelioma cell lines MSTO-211H, NCI-H2052, 
NCI-H28, NCI-H226 and NCI-H2452 (from ATCC) and 
all other lung cancer cell lines (sourced as previously 
described [60]) were cultured in RPMI supplemented 
with 10% FBS. The transformed normal mesothelial 
cell line MeT-5A (ATCC) was cultured in Medium 
199 with added 10% FBS, 2% HEPES, 0.1% Trace 
Elements B, 0.02% (100 μg/ml) EGF, 0.028% (1 mg/ml) 
Hydrocortisone, 0.05% (10 mg/ml) Insulin, and 0.01% 
(2 mg/ml) selenium acid.
RNA and protein extraction
To screen for correlative expression, total RNA 
and protein were extracted in parallel from the same 
samples using an RNA/DNA/protein purification kit 
(Norgen). In other experiments, total RNA was extracted 
using RNeasy kits (Qiagen) with on-column DNase 
digestion. Fractionated protein extracts were prepared 
by sequential extraction in NP-40 buffer (0.5% NP-40, 
25 mM Tris pH7.9, 150 mM NaCl), Dignam buffer C 
(20 mM HEPES pH7.9, 25% glycerol, 0.42 mM NaCl, 
1.5 mM MgCl, 0.2 mM EDTA) and Laemmli buffer (50 
mM Tris pH6.8, 2% SDS, 10% glycerol). Alternatively, 
whole cell protein extracts were prepared by direct 
addition to cells of hot Laemmli buffer and incubation 
at 110°C for 10mins with intermittent vortexing. The 
protein concentration of each sample was determined 




cDNA was reverse transcribed from 1 μg RNA 
with RevertAid H-minus M-MuLV reverse transcriptase 
(Fermentas) using an oligodT primer (Promega). 
Quantitative real-time RT-PCR (qRT-PCR) was performed 
in triplicate using SYBR Green Supermix and a real-time 
PCR detection system (Bio-rad). The primer pairs used were: 
BAP1 (For: 5′-CAGCCCTGAGAGCAAAGGATATG-3′, 
Rev: 5′-ATGGTCCGCACTGCACTAAG-3′), HDAC1 
(For: 5′-ACGGGATTGATGACGAGTCCTATG-3′, Rev: 
5′-TGAGCCACACTGTAAGACCACC-3′), HDAC2 (For: 
5′-TTACTGATGCTTGGAGGAGGTGGC-3′, Rev: 5′- TGG 
ACACCAGGTGCATGAGGTAAC-3′) and β-actin (ACTB, 
For: 5′-CACCTTCTACAATGAGCTGCGTGTG-3′, Rev: 
5′-ATAGCACAGCCTGGATAGCAACGTAC-3′). Samples 
underwent 2-step amplification at 94°C (30 s) and 60°C 
(60 s); melt curves were analyzed after 40 cycles. The Cq 
values for test genes were normalized to ACTB and relative 
expression represented as 2-[∆∆Cq].
Immunoblotting and antibodies
Equal amounts of lysates for comparator samples 
were subject to immunoblotting. Following resolution by 
10% SDS-PAGE, proteins were transferred to BiotraceNT 
membrane (VWR) and incubated with primary antibodies. 
Antibodies used were: mouse anti-BAP1 (C-4, Santa 
Cruz), anti-P53 (sc-126, Santa Cruz) and anti-β-actin 
(ab6276, Abcam), rabbit anti-HDAC2 (H54, Santa Cruz), 
goat anti-HDAC1 (C19, Santa Cruz). Proteins were 
visualized using donkey anti-mouse, anti-rabbit or anti-
sheep secondary antibodies conjugated to the IRDyes 
IR680-LT, or IR800 (LI-COR) and the LI-COR Odyssey 
2.1 system; 16-bit images were analyzed and quantified 
using the Odyssey analysis software.
RNA interference and DUB siRNA library screen
A custom designed DUB siRNA library consisting 
of pools of four oligos for each of 92 human DUBs 
(Qiagen) and control siRNAs were previously used to 
prepare a library of fractionated protein extracts from 
A549 cells [14]. To screen for the effect of each DUB 
on HDAC levels, samples from this nuclear extract 
library were divided across four 4%–12% gradient 
gels that were run and processed in parallel. Following 
immunoblotting, the HDACs were imaged in separate 
channels and bands were quantified using the Odyssey 
system; the amount of HDAC2 was expressed relative to 
the amount of HDAC1. The value for each sample was 
then normalized to the median value for the corresponding 
immunoblot. Mean values were derived from two 
independent immunoblotting runs, before collation and 
ranking of the dataset. The individual siRNA sequences 
from each pool were used for initial validation. Two of 
these siRNAs hs_BAP1_3 (SI00066710) and hs_BAP1_5 
(SI03036390) were used for follow-up studies together 
with hs_HDAC1_6 (SI02663472) and hs_HDAC2_1 
(SI00434952) (Qiagen). Non-targeting control siRNAs 
used were siC (AllStars, Qiagen), and siCON1 (D-
001210–01) or siCON2 (D-001210–02) from Dharmacon. 
For immunoblotting experiments, cells were seeded at 
6x104 (A549 and NCI-H460) or 1.5x105 (MSTO-211H 
and COR-L23) cells per well in 6-well plates, respectively, 
transfected the following day with 40 nM siRNA using 
Oligofectamine (Invitrogen), and harvested after 72 hr.
Inhibitors
Cells were treated with the following HDAC 
inhibitors: pan-HDAC vorinostat (Selleck) and tricho-
statin A (TSA, Sigma), class I selective mocetinostat 
(MGCD01032, Selleck) and class IIa selective MC1568 
(Selleck). In cyclo heximide chase experiments, 
cycloheximide (Sigma) was added to cells at 10 μg/
ml for periods of up to 6 hr. In proteasome inhibition 
experiments, epoxomicin (Calbiochem) was added to 
cells at 50 nM for 6 hr.
HDAC activity assay
A549 or MSTO-211H cells were seeded in 96-
well plates at a density of 4000 or 6000 cells per well, 
respectively. Treatment with 250 nM TSA for 16 hr, or 
5 μM vorinostat for 2 hr, was used a positive control 
in siRNA experiments. Cells were reverse transfected 
using Lipofectamine RNAiMax (Invitrogen) with 20 nM 
siRNAs targeting HDACs or DUBs, or a non-targeting 
siRNA (siC) or reagent only (mock). Total cellular HDAC 
activity was assayed 48 hr later using the HDAC GloI/
II Assay (Promega) in non-lytic format and normalized 
for cell viability. Parallel lysates were collected from 96-
well plates for immunoblotting; equivalent volumes were 
loaded without BCA assay.
Cell viability assays
The cellular toxicity of HDAC inhibitors was titrated 
in untransfected mesothelioma cell lines. For knockdown 
experiments, 4000 MSTO-211H cells were seeded into 96-
well plates and reverse transfected for 72 hr with 20 nM 
siRNA using RNAiMax. Cells were treated with vehicle 
(0.1% DMSO) or HDAC inhibitors at their LC30 (2.5 μM 
vorinostat, 1.25 μM mocetinostat, 20 μM MC1568) for 
the final 48 hr prior to analysis, with the media and drug 
replaced every 24 hr. The relative number of viable cells 
were determined, based on proportionality with the amount 
of ATP present, using the CellTitre-Glo assay (Promega).
Statistics
All statistical tests were performed using GraphPad 
Prism version 6.00 for Mac.
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